Literature DB >> 19363033

Biological responses to arsenic compounds.

Leonidas C Platanias1.   

Abstract

Arsenic is a metalloid that generates various biological effects on cells and tissues. Depending on the specific tissue exposed and the time and degree of exposure, diverse responses can be observed. In humans, prolonged and/or high dose exposure to arsenic can have a variety of outcomes, including the development of malignancies, severe gastrointestinal toxicities, diabetes, cardiac arrhythmias, and death. On the other hand, one arsenic derivative, arsenic trioxide (As(2)O(3)), has important antitumor properties. This agent is a potent inducer of antileukemic responses, and it is now approved by the Food and Drug Administration for the treatment of acute promyelocytic leukemia in humans. The promise and therapeutic potential of arsenic and its various derivatives have been exploited for hundreds of years. Remarkably, research focused on the potential use of arsenic compounds in the treatment of human diseases remains highly promising, and it is an area of active investigation. An emerging approach of interest and therapeutic potential involves efforts to target and block cellular pathways activated in a negative feedback manner during treatment of cells with As(2)O(3). Such an approach may ultimately provide the means to selectively enhance the suppressive effects of this agent on malignant cells and render normally resistant tumors sensitive to its antineoplastic properties.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19363033      PMCID: PMC2707240          DOI: 10.1074/jbc.R900003200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  61 in total

Review 1.  The TOR pathway: a target for cancer therapy.

Authors:  Mary-Ann Bjornsti; Peter J Houghton
Journal:  Nat Rev Cancer       Date:  2004-05       Impact factor: 60.716

2.  Arsenic trioxide inhibits the growth of A498 renal cell carcinoma cells via cell cycle arrest or apoptosis.

Authors:  Woo Hyun Park; Yeon Hee Cho; Chul Won Jung; Joon Oh Park; Kihyun Kim; Young Hyuck Im; Mark H Lee; Won Ki Kang; Keunchil Park
Journal:  Biochem Biophys Res Commun       Date:  2003-01-03       Impact factor: 3.575

3.  Arsenic trioxide causes redistribution of cell cycle, caspase activation, and GADD expression in human colonic, breast, and pancreatic cancer cells.

Authors:  Xinquan Li; Xianzhong Ding; Thomas E Adrian
Journal:  Cancer Invest       Date:  2004       Impact factor: 2.176

4.  Arsenic inhibition of the JAK-STAT pathway.

Authors:  Haiyun Y Cheng; Ping Li; Michael David; Thomas E Smithgall; Lili Feng; Michael W Lieberman
Journal:  Oncogene       Date:  2004-04-29       Impact factor: 9.867

5.  Ingested arsenic and internal cancer: a historical cohort study followed for 33 years.

Authors:  T Tsuda; A Babazono; E Yamamoto; N Kurumatani; Y Mino; T Ogawa; Y Kishi; H Aoyama
Journal:  Am J Epidemiol       Date:  1995-02-01       Impact factor: 4.897

6.  JNK activation is a mediator of arsenic trioxide-induced apoptosis in acute promyelocytic leukemia cells.

Authors:  Kelly Davison; Koren K Mann; Samuel Waxman; Wilson H Miller
Journal:  Blood       Date:  2003-12-30       Impact factor: 22.113

7.  Arsenite sensitizes human melanomas to apoptosis via tumor necrosis factor alpha-mediated pathway.

Authors:  Vladimir N Ivanov; Tom K Hei
Journal:  J Biol Chem       Date:  2004-03-17       Impact factor: 5.157

8.  Arsenic trioxide uses caspase-dependent and caspase-independent death pathways in myeloma cells.

Authors:  Jennifer McCafferty-Grad; Nizar J Bahlis; Nancy Krett; Tatiana M Aguilar; Isildinha Reis; Kelvin P Lee; Lawrence H Boise
Journal:  Mol Cancer Ther       Date:  2003-11       Impact factor: 6.261

9.  Incidence of internal cancers and ingested inorganic arsenic: a seven-year follow-up study in Taiwan.

Authors:  H Y Chiou; Y M Hsueh; K F Liaw; S F Horng; M H Chiang; Y S Pu; J S Lin; C H Huang; C J Chen
Journal:  Cancer Res       Date:  1995-03-15       Impact factor: 12.701

Review 10.  Cancer risks from arsenic in drinking water.

Authors:  A H Smith; C Hopenhayn-Rich; M N Bates; H M Goeden; I Hertz-Picciotto; H M Duggan; R Wood; M J Kosnett; M T Smith
Journal:  Environ Health Perspect       Date:  1992-07       Impact factor: 9.031

View more
  49 in total

1.  Arsenic exposure and toxicology: a historical perspective.

Authors:  Michael F Hughes; Barbara D Beck; Yu Chen; Ari S Lewis; David J Thomas
Journal:  Toxicol Sci       Date:  2011-07-12       Impact factor: 4.849

2.  A copper chelate of thiosemicarbazone NSC 689534 induces oxidative/ER stress and inhibits tumor growth in vitro and in vivo.

Authors:  Chad N Hancock; Luke H Stockwin; Bingnan Han; Raymond D Divelbiss; Jung Ho Jun; Sanjay V Malhotra; Melinda G Hollingshead; Dianne L Newton
Journal:  Free Radic Biol Med       Date:  2010-11-04       Impact factor: 7.376

3.  Oxidative inactivation of the lipid phosphatase phosphatase and tensin homolog on chromosome ten (PTEN) as a novel mechanism of acquired long QT syndrome.

Authors:  Xiaoping Wan; Adrienne T Dennis; Carlos Obejero-Paz; Jeffrey L Overholt; Jorge Heredia-Moya; Kenneth L Kirk; Eckhard Ficker
Journal:  J Biol Chem       Date:  2010-11-20       Impact factor: 5.157

4.  Autophagy modification augmented the treatment effects initiated by arsenic trioxide in NB4 cells.

Authors:  YaLi Ren; YanLing Xie; LiJun Chai; ShuHe Wang; Ming Cheng
Journal:  Med Oncol       Date:  2010-01-27       Impact factor: 3.064

5.  Mitochondrial biogenesis drives tumor cell proliferation.

Authors:  Ubaldo E Martinez-Outschoorn; Stephanos Pavlides; Federica Sotgia; Michael P Lisanti
Journal:  Am J Pathol       Date:  2011-05       Impact factor: 4.307

6.  Arsenic trioxide and the phosphoinositide 3-kinase/akt pathway in chronic lymphocytic leukemia.

Authors:  Dennis J Goussetis; Leonidas C Platanias
Journal:  Clin Cancer Res       Date:  2010-07-09       Impact factor: 12.531

7.  Arsenic trioxide inhibits cholangiocarcinoma cell growth and induces apoptosis.

Authors:  Fei Zhong; Shineng Zhang; Chunkui Shao; Jing Yang; Xiangyuan Wu
Journal:  Pathol Oncol Res       Date:  2009-12-12       Impact factor: 3.201

8.  Arsenic inhibits autophagic flux, activating the Nrf2-Keap1 pathway in a p62-dependent manner.

Authors:  Alexandria Lau; Yi Zheng; Shasha Tao; Huihui Wang; Samantha A Whitman; Eileen White; Donna D Zhang
Journal:  Mol Cell Biol       Date:  2013-04-15       Impact factor: 4.272

9.  Associations between arsenic exposure and global posttranslational histone modifications among adults in Bangladesh.

Authors:  Yana Chervona; Megan N Hall; Adriana Arita; Fen Wu; Hong Sun; Hsiang-Chi Tseng; Eunus Ali; Mohammad Nasir Uddin; Xinhua Liu; Maria Antonietta Zoroddu; Mary V Gamble; Max Costa
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-10-12       Impact factor: 4.254

10.  Basic mechanisms of arsenic trioxide (ATO)-induced apoptosis in human leukemia (HL-60) cells.

Authors:  Clement Yedjou; Paul Tchounwou; John Jenkins; Robert McMurray
Journal:  J Hematol Oncol       Date:  2010-08-26       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.